MeiraGTx Holdings plc filings document a clinical-stage genetic medicines company with ordinary shares listed on Nasdaq under MGTX. The company’s 8-K reports cover material definitive agreements, collaboration and license arrangements, asset purchases for genetic-medicine programs, Regulation FD clinical disclosures, operating and financial results, and amendments to note and warrant financing arrangements.
Its proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related corporate-governance disclosures. The filing record also documents capital structure, subsidiary guarantor arrangements, risk-oriented clinical and regulatory disclosures, and program-specific matters involving AAV-hAQP1, AAV-AIPL1, RPGR-related X-linked retinitis pigmentosa assets, and riboswitch technology.
MeiraGTx Holdings plc chief development officer Penny Renee Fleck reported compensation-related equity grants. She received 100,000 restricted share units, each convertible into one ordinary share upon vesting, and a stock option for 100,000 ordinary shares at an exercise price of $9.97 per share, vesting over several years with final option expiration on May 1, 2036.
MeiraGTx Holdings plc filed an initial insider ownership report for Penny Renee Fleck, who serves as Chief Development Officer. This Form 3 shows no reported transactions, derivative positions, or holdings, indicating a baseline disclosure of her status as a reporting officer without current share activity in this filing.
MeiraGTx Holdings plc reported Q1 2026 results with service revenue of $293,000 and a net loss of $46.3 million, compared with $40.0 million a year earlier. Operating expenses were $41.1 million, driven mainly by research and development and manufacturing costs.
Cash, cash equivalents and restricted cash totaled $73.8 million at March 31, 2026, and management expects liquidity, including an additional $100.0 million public equity raise completed in Q2 2026 and a tax incentive receivable, to fund operations for at least twelve months, including a $25.0 million debt repayment due in June.
The company highlighted several strategic transactions: a new asset purchase agreement with Janssen to reacquire its RPGR retinal gene therapy program for an upfront $25.0 million plus contingent milestones and royalties; a collaboration with Lilly that brought an upfront $75.0 million and potential milestones of over $400.0 million; and a broad AI-enabled neurology collaboration with Hologen, featuring a committed $200.0 million upfront payment (of which $105.0 million had been received by March 31, 2026) and up to an additional $230.0 million in program funding.
MeiraGTx Holdings plc reported first quarter 2026 results and highlighted major regulatory, pipeline and financing milestones. Service revenue was $0.3 million for the quarter, while net loss widened to $46.3 million, or $0.57 per share. Cash, cash equivalents and restricted cash totaled $73.8 million as of March 31, 2026.
The company received FDA Breakthrough Therapy Designation for AAV2-hAQP1 in radiation-induced xerostomia and reported positive three-year Phase 1 data. It also entered an asset purchase agreement with Johnson & Johnson to reacquire botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa, which already has Fast Track, Orphan Drug and EU PRIME designations.
MeiraGTx strengthened its balance sheet with a $100 million public equity financing and expects, together with a $14.7 million tax incentive receivable and a remaining $95 million upfront payment from Hologen, to fund operations into the second half of 2028, while covering a $25 million upfront payment to J&J and scheduled debt repayments of $25 million in June 2026 and $50 million in July 2027.
MeiraGTx Holdings plc ownership disclosure: Adage Capital Management, L.P. and related reporting persons report 4,000,000 Ordinary Shares, representing 4.91% of the class. The percentage is calculated using 81,446,126 Ordinary Shares outstanding as of March 30, 2026, per the company's Form 10-K.
The filing (Amendment No. 6 to a Schedule 13G) attributes shared voting and shared dispositive power over the 4,000,000 shares to Adage and individuals Robert Atchinson and Phillip Gross. The business address for the reporting persons is noted as 200 Clarendon Street, Boston, Massachusetts.
MeiraGTx Holdings plc is asking shareholders to elect three Class II directors and ratify Ernst & Young LLP as independent auditor at its 2026 virtual annual meeting. The meeting will be held on June 11, 2026 at 10:00 a.m. Eastern Time via webcast.
Shareholders of record as of April 21, 2026, holding 92,573,523 ordinary shares, may attend and vote, with a quorum reached when at least one third of voting share capital is represented. The board recommends voting for all director nominees and for auditor ratification.
The proxy also outlines corporate governance practices, committee structures and 2025 executive pay. In 2025, CEO Alexandria Forbes received total compensation of $8.33 million, including an $840,000 salary, $1.65 million bonus and equity awards. CFO/COO Richard Giroux received $8.15 million, and CMO Robert Zeldin received $1.62 million.
MeiraGTx Holdings plc Chief Medical Officer Robert K. Zeldin reported an administrative update related to equity compensation. On the vesting of an award, 7,814 Ordinary Shares were withheld to pay taxes at an indicated value of $7.73 per share. Following this tax-withholding disposition, he beneficially owns 146,204 Ordinary Shares directly. This amended filing corrects the previously reported number of shares withheld and the post-transaction holdings, and also adjusts total beneficial ownership down by two shares to address earlier rounding errors.
Perceptive Advisors and affiliated entities report beneficial ownership of 11,742,117 MeiraGTx ordinary shares, representing 12.6% of the class. This percentage is based on 92,557,237 outstanding shares, including shares from warrant and option exercises and deferred share unit settlements.
On April 17, 2026, Perceptive’s Master Fund purchased 555,555 ordinary shares at $9.00 per share in MeiraGTx’s underwritten offering. Perceptive-related credit funds also hold warrants for 700,000 shares, with the exercise price adjusted to $8.00 per share under a March 25, 2026 notes purchase agreement amendment; these warrants were originally issued with exercise prices of $15.00 and $20.00 and expire on August 2, 2027.
MeiraGTx Holdings plc entered into a strategic collaboration and license agreement with Hologen focused on AAV-GAD and AAV-BDNF gene therapies and a proprietary CNS delivery device. The collaboration includes an upfront cash payment commitment of $200 million under existing framework agreements.
Of this amount, Hologen has previously paid $105 million, which was partly used to fund MeiraGTx Neuro US and to subscribe for shares in Hologen Neuro AI Limited (HNAI) and MeiraGTx Manufacturing Limited. After completion, Hologen is expected to own 70% of HNAI, with MeiraGTx Neuro UK owning 30%. Hologen will also hold a minority stake in MeiraGTx Manufacturing, with an option to increase its ownership up to 40% within twelve months of an additional share purchase, while MeiraGTx retains a later option to buy back Hologen’s MeiraGTx Manufacturing shares.